The Impact of Weight Loss Programs on Body Mass Index Trajectory in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Veterans Health Administration Study-Reference-Cited by-同舟云学术

The Impact of Weight Loss Programs on Body Mass Index Trajectory in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Veterans Health Administration Study

Published:2024-04-18 Issue: Volume: Page:
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Tang Helen¹^ORCID,Kaplan David E.²³^ORCID,Mahmud Nadim²³⁴⁵^ORCID

Affiliation:

1. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;

2. Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;

3. Department of Medicine, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA;

4. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA;

5. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Abstract

INTRODUCTION: Weight loss is the mainstay of management for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). We studied the impact of referral to MOVE!, a nationally implemented behavioral weight loss program, on weight in patients with MASLD. METHODS: This retrospective cohort study included 102,294 patients with MASLD from 125 Veterans Health Administration centers from 2008 to 2022. RESULTS: Most patients lost no significant weight or gained weight. Increased engagement with MOVE! was associated with a greater hazard of significant weight loss compared with no engagement. DISCUSSION: A minority of patients experienced significant weight loss through 5 years using lifestyle interventions alone.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference16 articles.

1. Global burden of liver disease: 2023 update;Devarbhavi;J Hepatol,2023

2. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030;Estes;J Hepatol,2018

3. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes;Ahmed;Clin Gastroenterol Hepatol,2015

4. Nonalcoholic fatty liver disease: Diagnosis and management guidelines from the AACE;Arnold;Am Fam Physician,2023

5. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology;Chalasani;Gastroenterology,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and GI Diseases: A Major Problem Weighing on Our Guts and Minds;American Journal of Gastroenterology;2024-06